@eliasegui.bsky.social
Breast Medical Oncologist | Born and raised @hospitalclinic | Research fellow @DFCI_BreastOnc/Harvard Med School | PhD student Translational Genomics @IDIBAPS | 🧬 Main focus: breast oncoIogy, IO and biomarkers.
Meet Dr. Elia Seguí (@eliasegui.bsky.social), a new Advanced Fellow at the Breast Oncology Center at Dana-Farber. Dr. Seguí specializes in #BreastCancer and #ImmunoOncology. She finds immense fulfillment in combining patient care with academic research.
15.01.2025 14:55 — 👍 6 🔁 1 💬 0 📌 0
Women are under-represented at senior levels in #academia globally, & across all #science 🧪 disciplines, as shown by these "scissor-shaped curves" ✂️
So how can we ever achieve #gender #equality?
We discuss various strategies in this #Cell Commentary
#WomeninSTEM
www.cell.com/cell/fulltex...
🧵 1/
Insightful translational study on chemo+IO in eTNBC dissecting chemo response vs IO response! Well done GBG! @cellpressnews.bsky.social #bcsm @oncoalert.bsky.social
22.11.2024 09:39 — 👍 11 🔁 2 💬 0 📌 0missing u all!
22.11.2024 15:54 — 👍 1 🔁 0 💬 0 📌 0For me it’s control over what I choose to expose myself to on a daily basis. I have thought a lot about quitting social media all together due to its negative impacts.
Looking for a space to share medical knowledge and research, be up to date. I don’t need an echo chamber but I do need sanity.
Definitely a must-read for anyone interested in the interplay between ER signaling and the tumor immune microenvironment. Incredible work by @ccortimd.bsky.social 👏👏
👉 Check it out here: doi.org/10.1016/j.ct...
Updated treatment algorithms for breast cancer now include adjuvant ribociclib and inavolisib, along with key trial names. Thrilled to see we're truly running out of space in HR+ disease—progress is here, with much more to come for all breast cancer subtypes!
17.11.2024 23:03 — 👍 71 🔁 16 💬 3 📌 2Seeing this explosion of activity on BlueSky, I can’t help but feel excited about the possibilities. Let’s make this a space dedicated to vibrant scientific discussions, true collaboration, and inclusion for everyone 🧬
17.11.2024 22:27 — 👍 3 🔁 0 💬 0 📌 0
Only 3 weeks to #SABCS24, a meeting that promises to significantly impact the way we treat breast cancer. It will feature phase 3 data with novel SERDs, novel ADCs, immunotherapy, ctDNA monitoring, important biomarker analyses & so much more. Here’s my top 10 abstracts list— see you in San Antonio!
17.11.2024 20:01 — 👍 94 🔁 34 💬 3 📌 5
